Linked Life Data

16153753

Source:http://linkedlifedata.com/resource/pubmed/id/16153753

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
18
pubmed:dateCreated
2006-5-8
pubmed:abstractText
In the present study we compared the ELISPOT and antibody in lymphocyte supernatants (ALS) assays as surrogate measures of mucosal immunity. In separate studies, 20 inpatient volunteers received oral doses of 6 x 10(8) or 4 x 10(9)cfu of ETEC strain E24377A (LT+, ST+, CS1+, CS3+) and 20 subjects received 1 (n = 9) or 2 (n = 11) oral doses of the attenuated ETEC vaccine, PTL-003 expressing CFA/II (CS1+ and CS3+) (2 x 10(9)cfu/dose). Peripheral blood mononuclear cells (PBMCs) from all subjects were assayed for anti-colonization factor or toxin-specific IgA antibody responses using the ALS and ELISPOT procedures. ALS responses were measured using a standard ELISA, as well as by time-resolved fluorescence (TRF). Following challenge with E24377A, significant anti-CS3, CS1 and LT ALS responses were detected in the lymphocyte supernatants of 75-95% of the subjects. A similar proportion (75%) of subjects mounted an ALS response to CFA/II antigen after vaccination with the PTL-003 vaccine. Inter-assay comparisons between ALS and ELISPOT methods also revealed a high degree of correlation in both immunization groups. ALS sensitivity versus the ELISPOT assay for LT, CS3 and CS1-specific responses following challenge were 95%, 94% and 78%, respectively and 83% for the ALS response to CFA/II antigen after vaccination with PTL-003. Correlation coefficients for the LT and CS3 antigens were 0.94 (p<0.001) and 0.82 (p<0.001), respectively after challenge and 0.78 (p<0.001) after vaccination. The association between ALS and ELISPOT for the CS1 antigen was however, significant only when ALS supernatants were tested by TRF (r = 0.91, p<0.001). These results demonstrate the value and flexibility of the ALS assay as an alternative to ELISPOT for the measurement of mucosal immune responses to ETEC antigens, particularly when the complexities of ELISPOT may make it impractical to perform.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3709-18
pubmed:dateRevised
2008-8-20
pubmed:meshHeading
pubmed-meshheading:16153753-Adult, pubmed-meshheading:16153753-Antibodies, Bacterial, pubmed-meshheading:16153753-Bacterial Toxins, pubmed-meshheading:16153753-Enterotoxins, pubmed-meshheading:16153753-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:16153753-Escherichia coli, pubmed-meshheading:16153753-Escherichia coli Infections, pubmed-meshheading:16153753-Escherichia coli Proteins, pubmed-meshheading:16153753-Escherichia coli Vaccines, pubmed-meshheading:16153753-Female, pubmed-meshheading:16153753-Fimbriae Proteins, pubmed-meshheading:16153753-Fluoroimmunoassay, pubmed-meshheading:16153753-Humans, pubmed-meshheading:16153753-Immunity, Mucosal, pubmed-meshheading:16153753-Immunoglobulin A, pubmed-meshheading:16153753-Immunologic Techniques, pubmed-meshheading:16153753-Leukocytes, Mononuclear, pubmed-meshheading:16153753-Male, pubmed-meshheading:16153753-Middle Aged, pubmed-meshheading:16153753-Sensitivity and Specificity, pubmed-meshheading:16153753-Vaccines, Attenuated
pubmed:year
2006
pubmed:articleTitle
Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.
pubmed:affiliation
Center for Immunization Research, Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, 624 N. Broadway, HH, Rm 205, Baltimore, MD 21205, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural